BofA Affirms Buy on Wingstop (WING), Cites Strong Growth and Brand Loyalty

Wingstop Inc. (NASDAQ:WING) is one of the high growth stocks outside tech analysts are bullish on. On July 18, Bank of America analyst Sara Senatore lowered the firm’s price target on Wingstop Inc. (NASDAQ:WING) from $430 to $420 while maintaining a Buy rating on the stock. At the current market price of $289.80, the revised target implies a potential upside of approximately 45%.

BofA Affirms Buy on Wingstop (WING), Cites Strong Growth and Brand Loyalty

The change in price target comes as part of a broader adjustment by BofA, which is updating estimates and valuation multiples for over 20 restaurant stocks ahead of earnings season. While the reduction in Wingstop’s target is modest, it reflects shifts in both sector expectations and general market conditions rather than a negative view of the company’s fundamentals.

Despite the slight trim in target price, Wingstop remains one of the firm’s top picks in the restaurant space. Investors continue to view it favorably due to its consistent same-store sales growth, digital ordering strength, and strong brand loyalty. Additionally, Wingstop’s asset-light business model, based on franchising, offers steady margins and scalability with relatively low capital risk.

As the earnings season approaches, analysts will be closely watching for updates on international expansion, pricing power, and how the company is navigating cost pressures.

Wingstop is a fast-casual restaurant chain focused on chicken wings, primarily operating through a franchise model.

While we acknowledge the risk and potential of WING as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than WING and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Most Profitable Consumer Stocks to Buy Now and 10 Best High-Margin Pharma Stocks to Buy Now.

Disclosure: None.